UNITED STATES PATENT AND TRADEMARK OFFICE

Trademark Electronic Search System (TESS)

TESS was last updated on Fri Oct 10 04:18:14 EDT 2003

Logout Please logout when you are done to release system resources allocated for you.

Start List At: OR Jump to record: **Record 2 out of 3**

Check Status *(TARR contains current status, correspondence address and attorney of record for this mark. Use the "Back" button of the Internet Browser to return to TESS)*

Typed Drawing

Word Mark	**TAXOL**
Goods and Services	IC 005. US 018. G & S: anti-cancer preparations. FIRST USE: 19911106. FIRST USE IN COMMERCE: 19911106
Mark Drawing Code	(1) TYPED DRAWING
Serial Number	74125254
Filing Date	December 20, 1990
Filed ITU	FILED AS ITU
Published for Opposition	August 20, 1991
Registration Number	1689497
Registration Date	May 26, 1992
Owner	(REGISTRANT) Bristol-Myers Squibb Company CORPORATION DELAWARE 345 Park Avenue New York NEW YORK 10017
Attorney of Record	NADINE FLYNN
Type of Mark	TRADEMARK
Register	PRINCIPAL
Affidavit Text	SECT 15. SECT 8 (6-YR). SECTION 8(10-YR) 20020201.
Renewal	1ST RENEWAL 20020201
Live/Dead Indicator	LIVE

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600LXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09  CA/CAplus records now contain indexing from 1907 to the
                  present
 NEWS  4  Jul 15  Data from 1960-1976 added to RDISCLOSURE
 NEWS  5  Jul 21  Identification of STN records implemented
 NEWS  6  Jul 21  Polymer class term count added to REGISTRY
 NEWS  7  Jul 22  INPADOC: Basic index (/BI) enhanced; Simultaneous Left and
                  Right Truncation available
 NEWS  8  AUG 05  New pricing for EUROPATFULL and PCTFULL effective
                  August 1, 2003
 NEWS  9  AUG 13  Field Availability (/FA) field enhanced in BEILSTEIN
 NEWS 10  AUG 15  PATDPAFULL: one FREE connect hour, per account, in
                  September 2003
 NEWS 11  AUG 15  PCTGEN: one FREE connect hour, per account, in
                  September 2003
 NEWS 12  AUG 15  RDISCLOSURE: one FREE connect hour, per account, in
                  September 2003
 NEWS 13  AUG 15  TEMA: one FREE connect hour, per account, in
                  September 2003
 NEWS 14  AUG 18  Data available for download as a PDF in RDISCLOSURE
 NEWS 15  AUG 18  Simultaneous left and right truncation added to PASCAL
 NEWS 16  AUG 18  FROSTI and KOSMET enhanced with Simultaneous Left and Righ
                  Truncation
 NEWS 17  AUG 18  Simultaneous left and right truncation added to ANABSTR
 NEWS 18  SEP 22  DIPPR file reloaded
 NEWS 19  SEP 25  INPADOC: Legal Status data to be reloaded
 NEWS 20  SEP 29  DISSABS now available on STN

 NEWS EXPRESS  OCTOBER 01 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 10:51:02 ON 10 OCT 2003

=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'CAPLUS' ENTERED AT 10:51:22 ON 10 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 10 Oct 2003  VOL 139 ISS 16
FILE LAST UPDATED: 9 Oct 2003  (20031009/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s hyaluronan and methotrexate
          2669 HYALURONAN
            34 HYALURONANS
          2672 HYALURONAN
                 (HYALURONAN OR HYALURONANS)
         12478 METHOTREXATE
            19 METHOTREXATES
         12480 METHOTREXATE
                 (METHOTREXATE OR METHOTREXATES)
L1            7 HYALURONAN AND METHOTREXATE

=> d L1 1-7 ibib abs hitrn

L1   ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2003:173470  CAPLUS
DOCUMENT NUMBER:          138:198677
TITLE:                    Use of hyaluronan as a protective agent in
                          chemotherapy for improved therapeutic protocols
INVENTOR(S):              Brown, Tracey Jean; Fox, Richard Mark
PATENT ASSIGNEE(S):       Meditech Research Limited, Australia
SOURCE:                   PCT Int. Appl., 96 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2003018062      A1   20030306       WO 2002-AU1160   20020827
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
```

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AU 2001-7302 A 20010827
AU 2001-9504 A 20011213

AB The invention relates to the field of chemotherapy of diseases, e.g. cell proliferation disorders including cancer. In particular, the invention discloses the use of **hyaluronan** (HA) as a protective agent in the treatment of subjects. HA is administered in conjunction with a chemotherapeutic agent to facilitate the prolonged administration of a dose of the chemotherapeutic agent to be administered to a subject. Owing to the protective effects of the HA, the dose of chemotherapeutic agent may be substantially higher than a generally accepted ED, which would otherwise be expected to cause unacceptable side effects in the subject.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:71908 CAPLUS
DOCUMENT NUMBER: 136:112640
TITLE: **Hyaluronan** as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
INVENTOR(S): Brown, Tracey; Fox, Richard
PATENT ASSIGNEE(S): Meditech Research Limited, Australia
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005852	A1	20020124	WO 2001-AU849	20010713
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2368525	A1	20020508	GB 2002-4331	20010713
EP 1301209	A1	20030416	EP 2001-951219	20010713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 760404	B2	20030515	AU 2001-72202	20010713
US 2003180382	A1	20030925	US 2003-88774	20030313

PRIORITY APPLN. INFO.: AU 2000-8795 A 20000714
WO 2001-AU849 W 20010713

AB The present invention relates to the enhancement of bioavailability of chemotherapeutic agents for the treatment of disease. In particular the present invention relates to a method of enhancing the bioavailability of a chemotherapeutic agent comprising the step of administering to a subject in need thereof a therapeutically effective amt. of **hyaluronan**. The present invention also relates to the treatment of a drug resistant disease whereby the drug resistance is overcome or alleviated with the use

of **hyaluronan** either alone or in combination with a chemotherapeutic agent. One disease that is frequently affected by both cellular resistance and bioavailability problems is cancer. The present invention also provides a method of treating cancer cells comprising the step of administering to a patient in thereof a therapeutically effective amt. of **hyaluronan**.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:798086 CAPLUS
DOCUMENT NUMBER: 135:348866
TITLE: RHAMM peptide conjugates for drug targeting
INVENTOR(S): Woloski, B. Michael R.; Williams, Ashley Martin; Sereda, Terrance Jimmy; Wiebe, Deanna June
PATENT ASSIGNEE(S): Cangene Corporation, Can.
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001080899	A2	20011101	WO 2001-CA533	20010420
WO 2001080899	A3	20020906		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1274461	A2	20030115	EP 2001-923439	20010420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2000-198613P P 20000420
WO 2001-CA533 W 20010420
OTHER SOURCE(S): MARPAT 135:348866

AB The present invention provides protein conjugates having a glucose-aminoglycan-targeting domain conjugated directly or indirectly to a therapeutically useful protein via chem. or peptidyl linkage. A conjugate of the invention is disclosed in which a **hyaluronan** -binding protein is a receptor for hyaluronic acid-mediated mobility (RHAMM). The protein conjugates selectively target certain tissues and organs and are useful for treating or preventing various physiol. and pathol. conditions. Methods of their use and prepn. are described.

L1 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:545502 CAPLUS
DOCUMENT NUMBER: 135:117219
TITLE: Hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms
INVENTOR(S): Yu, Baofa
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052868	A1	20010726	WO 2001-US1737	20010118
WO 2001052868	C2	20030116		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2002044919	A1	20020418	US 2001-765060	20010117

PRIORITY APPLN. INFO.: US 2000-177024P P 20000119

AB Methods are provided for treating neoplasms, tumors and cancers, using one or more haptens and coagulation agents or treatments, alone or in combination with other anti-neoplastic agents or treatments. Also provided are combinations, and kits contg. the combinations for effecting the therapy.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:493422 CAPLUS
DOCUMENT NUMBER: 133:109985
TITLE: A composition and method for the enhancement of the efficacy of drugs
INVENTOR(S): Brown, Tracey
PATENT ASSIGNEE(S): Meditech Research Limited, Australia
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041730	A1	20000720	WO 2000-AU4	20000106

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1140198	A1	20011010	EP 2000-902481	20000106

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

JP 2002534484	T2	20021015	JP 2000-593339	20000106
NZ 512676	A	20030131	NZ 2000-512676	20000106
ZA 2001005492	A	20021003	ZA 2001-5492	20010703

PRIORITY APPLN. INFO.:
AU 1999-8131 A 19990113
AU 1999-3938 A 19991109
WO 2000-AU4 W 20000106

AB The present invention relates to the enhancement of the efficacy of drugs, and more particularly, with overcoming the resistance of cells or organisms to drugs. In particular, the present invention provides a method for enhancing the effectiveness of a cytotoxic or antineoplastic agent, comprising the step of co-administering said agent with

hyaluronan, wherein co-administration with **hyaluronan** enhances the agent's cancer cell-killing potential. There was an increase in 5-FU uptake by tumors when 5-FU was injected with hyaluronic acid.
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:316588 CAPLUS
DOCUMENT NUMBER: 130:320837
TITLE: Oligosaccharides reactive with **hyaluronan** -binding protein, monoclonal antibodies recognizing **hyaluronan**-binding protein, and use in cancer therapy
INVENTOR(S): Toole, Bryan P.; Banerjee, Shib D.
PATENT ASSIGNEE(S): Trustees of Tufts College, USA
SOURCE: U.S., 22 pp., Cont.-in-part of U.S. Ser. No. 899,249, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5902795	A	19990511	US 1994-306150	19940914
PRIORITY APPLN. INFO.:			US 1992-899249	19920616

AB **Hyaluronan**-binding protein (HABP) is expressed on the cell surface during tumor cell and endothelial cell migration and during capillary-like tubule formation. Monoclonal antibodies and **hyaluronan** oligosaccharides are described which specifically recognize HABP and can be used to (1) inhibit tumor growth by preventing tumor vascularization, (2) inhibit tumor cell migration and (3) image tumors.
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:169161 CAPLUS
DOCUMENT NUMBER: 131:17430
TITLE: Production and elimination of **hyaluronan** in rheumatoid arthritis patients: estimation with a loading test
AUTHOR(S): Torsteinsdottir, Ingunn; Groth, Torgny; Lindqvist, Ulla
CORPORATE SOURCE: Department of Clinical Chemistry, University Hospital, Uppsala, S-751 85, Swed.
SOURCE: Seminars in Arthritis and Rheumatism (1999), 28(4), 268-279
CODEN: SAHRBF; ISSN: 0049-0172
PUBLISHER: W. B. Saunders Co.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB To evaluate the benefit of detg. the maximal elimination rate (Vmax) and the endogenous prodn. of **hyaluronan** (HYA) in relation to the basal HYA concn. (c0) in rheumatoid arthritis (RA) patients; and to evaluate the compatibility of a new model for HYA kinetics, taking renal elimination into sep. account in the overall clearance of HYA from the blood. The calcns. of prodn. and elimination of HYA were based on the HYA loading test, which was performed in 21 patients with RA and 15 healthy controls. A blood sample was drawn before the loading test, followed by an i.v. injection of HYA as a single bolus dose of 7.5 mg. Blood samples were taken regularly during the next 60 min. A theor. model with computational anal. of the data collected was used for calcg. HYA prodn.

and elimination. Patients with RA had significantly higher c0 than healthy controls, although in 10 of 21 patients c0 was within the normal range. The RA patients also had higher Vmax than healthy controls, but the difference was not significant. The calcd. prodn. of HYA was increased in RA patients and correlated with c0. The new model for HYA kinetics, in which the renal elimination was taken sep. into account, proved to be more compatible than the previous model. The HYA loading test can help det. whether the increased serum level of HYA in RA patients is due to a high prodn. or reduced elimination of HYA or both.

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s hyaluronan and paclitaxel
2669 HYALURONAN
34 HYALURONANS
2672 HYALURONAN
(HYALURONAN OR HYALURONANS)
5434 PACLITAXEL
15 PACLITAXELS
5434 PACLITAXEL
(PACLITAXEL OR PACLITAXELS)
L2 4 HYALURONAN AND PACLITAXEL

=> d L2 1-4 ibib abs hitrn

L2 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:808942 CAPLUS
DOCUMENT NUMBER: 137:43795
TITLE: Identification of small molecule binding sites within proteins using phage display technology
AUTHOR(S): Rodi, D. J.; Agoston, G. E.; Manon, R.; Lapcevich, R.; Green, S. J.; Makowski, L.
CORPORATE SOURCE: Department of Discovery Research, EntreMed, Inc., Rockville, MD, 20850, USA
SOURCE: Combinatorial Chemistry and High Throughput Screening (2001), 4(7), 553-572
CODEN: CCHSFU; ISSN: 1386-2073
PUBLISHER: Bentham Science Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Affinity selection of peptides displayed on phage particles was used as the basis for mapping mol. contacts between small mol. ligands and their protein targets. Anal. of the crystal structures of complexes between proteins and small mol. ligands revealed that virtually all ligands of mol. wt. 300 Da or greater have a continuous binding epitope of 5 residues or more. This observation led to the development of a technique for binding site identification which involves statistical anal. of an affinity-selected set of peptides obtained by screening of libraries of random, phage-displayed peptides against small mols. attached to solid surfaces. A random sample of the selected peptides is sequenced and used as input for a similarity scanning program which calcs. cumulative similarity scores along the length of the putative receptor. Regions of the protein sequence exhibiting the highest similarity with the selected peptides proved to have a high probability of being involved in ligand binding. This technique has been employed successfully to map the contact residues in multiple known targets of the anticancer drugs **paclitaxel** (Taxol), docetaxel (Taxotere) and 2-methoxyestradiol and the glycosaminoglycan **hyaluronan**, and to identify a novel **paclitaxel** receptor [1]. These data corroborate the observation that the binding properties of peptides displayed on the surface of phage particles can mimic the binding properties of peptides in naturally occurring proteins. It follows directly that structural context is relatively unimportant for detg. the binding properties of these

disordered peptides. This technique represents a novel, rapid, high resoln. method for identifying potential ligand binding sites in the absence of three-dimensional information and has the potential to greatly enhance the speed of development of novel small mol. pharmaceuticals.

REFERENCE COUNT: 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:545502 CAPLUS
DOCUMENT NUMBER: 135:117219
TITLE: Hapten-coagulation agent-antineoplastic agent combinations for treating neoplasms
INVENTOR(S): Yu, Baofa
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052868	A1	20010726	WO 2001-US1737	20010118
WO 2001052868	C2	20030116		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002044919	A1	20020418	US 2001-765060	20010117

PRIORITY APPLN. INFO.: US 2000-177024P P 20000119

AB Methods are provided for treating neoplasms, tumors and cancers, using one or more haptens and coagulation agents or treatments, alone or in combination with other anti-neoplastic agents or treatments. Also provided are combinations, and kits contg. the combinations for effecting the therapy.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:493422 CAPLUS
DOCUMENT NUMBER: 133:109985
TITLE: A composition and method for the enhancement of the efficacy of drugs
INVENTOR(S): Brown, Tracey
PATENT ASSIGNEE(S): Meditech Research Limited, Australia
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000041730	A1	20000720	WO 2000-AU4	20000106
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1140198	A1	20011010	EP 2000-902481	20000106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002534484	T2	20021015	JP 2000-593339	20000106
NZ 512676	A	20030131	NZ 2000-512676	20000106
ZA 2001005492	A	20021003	ZA 2001-5492	20010703

PRIORITY APPLN. INFO.:	AU 1999-8131	A	19990113
	AU 1999-3938	A	19991109
	WO 2000-AU4	W	20000106

AB The present invention relates to the enhancement of the efficacy of drugs, and more particularly, with overcoming the resistance of cells or organisms to drugs. In particular, the present invention provides a method for enhancing the effectiveness of a cytotoxic or antineoplastic agent, comprising the step of co-administering said agent with **hyaluronan**, wherein co-administration with **hyaluronan** enhances the agent's cancer cell-killing potential. There was an increase in 5-FU uptake by tumors when 5-FU was injected with hyaluronic acid.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	1999:64680 CAPLUS
DOCUMENT NUMBER:	130:115045
TITLE:	**Paclitaxel** compositions containing hyaluronic acid of a molecular weight of less than 750.000 Da
INVENTOR(S):	Asculai, Samuel S.; Moore, Adrian
PATENT ASSIGNEE(S):	Hyal Pharmaceutical Corporation, Can.
SOURCE:	PCT Int. Appl., 17 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902151	A1	19990121	WO 1998-CA660	19980708
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2208924	AA	19990109	CA 1997-2208924	19970709
AU 9882031	A1	19990208	AU 1998-82031	19980708

PRIORITY APPLN. INFO.:	CA 1997-2208924	A	19970709
	WO 1998-CA660	W	19980708

AB **Hyaluronan** is used to deliver effective dosage amts. of **paclitaxel** to a patient which medicine is present in a dosage amt. much less than the usual amt. presently being used when treating a patient with cancer. Taxol at 2.5 mg/kg and **hyaluronan** at 7.5 mg/kg decreased the wt. of tumors in mice from 470 to 391 g.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s L1 and toxicity
        292913 TOXICITY
         10626 TOXICITIES
        296196 TOXICITY
                  (TOXICITY OR TOXICITIES)
L3            2 L1 AND TOXICITY

=> d L3 1-2 ibib abs hitrn

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2003:173470  CAPLUS
DOCUMENT NUMBER:          138:198677
TITLE:                    Use of hyaluronan as a protective agent in
                          chemotherapy for improved therapeutic protocols
INVENTOR(S):              Brown, Tracey Jean; Fox, Richard Mark
PATENT ASSIGNEE(S):       Meditech Research Limited, Australia
SOURCE:                   PCT Int. Appl., 96 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2003018062      A1   20030306       WO 2002-AU1160   20020827
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
PRIORITY APPLN. INFO.:                  AU 2001-7302     A  20010827
                                        AU 2001-9504     A  20011213
AB   The invention relates to the field of chemotherapy of diseases, e.g. cell
     proliferation disorders including cancer. In particular, the invention
     discloses the use of hyaluronan (HA) as a protective agent in
     the treatment of subjects. HA is administered in conjunction with a
     chemotherapeutic agent to facilitate the prolonged administration of a
     dose of the chemotherapeutic agent to be administered to a subject. Owing
     to the protective effects of the HA, the dose of chemotherapeutic agent
     may be substantially higher than a generally accepted ED, which would
     otherwise be expected to cause unacceptable side effects in the subject.
REFERENCE COUNT:          4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:         2002:71908  CAPLUS
DOCUMENT NUMBER:          136:112640
TITLE:                    Hyaluronan as a cytotoxic agent, drug
                          pre-sensitizer and chemo-sensitizer in the treatment
                          of disease
INVENTOR(S):              Brown, Tracey; Fox, Richard
PATENT ASSIGNEE(S):       Meditech Research Limited, Australia
SOURCE:                   PCT Int. Appl., 70 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
```

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005852	A1	20020124	WO 2001-AU849	20010713
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2368525	A1	20020508	GB 2002-4331	20010713
EP 1301209	A1	20030416	EP 2001-951219	20010713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 760404	B2	20030515	AU 2001-72202	20010713
US 2003180382	A1	20030925	US 2003-88774	20030313

PRIORITY APPLN. INFO.: AU 2000-8795 A 20000714
WO 2001-AU849 W 20010713

AB The present invention relates to the enhancement of bioavailability of chemotherapeutic agents for the treatment of disease. In particular the present invention relates to a method of enhancing the bioavailability of a chemotherapeutic agent comprising the step of administering to a subject in need thereof a therapeutically effective amt. of **hyaluronan**. The present invention also relates to the treatment of a drug resistant disease whereby the drug resistance is overcome or alleviated with the use of **hyaluronan** either alone or in combination with a chemotherapeutic agent. One disease that is frequently affected by both cellular resistance and bioavailability problems is cancer. The present invention also provides a method of treating cancer cells comprising the step of administering to a patient in thereof a therapeutically effective amt. of **hyaluronan**.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s L2 and toxicity
        292913 TOXICITY
         10626 TOXICITIES
        296196 TOXICITY
                 (TOXICITY OR TOXICITIES)
L4           0 L2 AND TOXICITY

=> s hyaluronan and fluorouracil
          2669 HYALURONAN
            34 HYALURONANS
          2672 HYALURONAN
                 (HYALURONAN OR HYALURONANS)
         14497 FLUOROURACIL
           268 FLUOROURACILS
         14510 FLUOROURACIL
                 (FLUOROURACIL OR FLUOROURACILS)
L5           5 HYALURONAN AND FLUOROURACIL

=> d L5 1-5 ibib abs hitrn

L5   ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:        2003:173470  CAPLUS
DOCUMENT NUMBER:         138:198677
TITLE:                   Use of hyaluronan as a protective agent in
```

chemotherapy for improved therapeutic protocols
INVENTOR(S): Brown, Tracey Jean; Fox, Richard Mark
PATENT ASSIGNEE(S): Meditech Research Limited, Australia
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018062	A1	20030306	WO 2002-AU1160	20020827

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AU 2001-7302 A 20010827
AU 2001-9504 A 20011213

AB The invention relates to the field of chemotherapy of diseases, e.g. cell proliferation disorders including cancer. In particular, the invention discloses the use of **hyaluronan** (HA) as a protective agent in the treatment of subjects. HA is administered in conjunction with a chemotherapeutic agent to facilitate the prolonged administration of a dose of the chemotherapeutic agent to be administered to a subject. Owing to the protective effects of the HA, the dose of chemotherapeutic agent may be substantially higher than a generally accepted ED, which would otherwise be expected to cause unacceptable side effects in the subject.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:9651 CAPLUS
DOCUMENT NUMBER: 139:138568
TITLE: Dry film made of hylan to prevent adhesion between two healing tissue surfaces
AUTHOR(S): Balazs, Endre A.; Larsen, Nancy E.; Leshchiner, Edward A.; Boney, John D.; Mitlitski, Vadim; Parent, Edward G.; Whetstone, Julie L.
CORPORATE SOURCE: Matrix Biology Institute, Ridgefield, NJ, 07657, USA
SOURCE: Hyaluronan, [Proceedings of the International Cellucon Conference], 12th, Wrexham, United Kingdom, 2000 (2002), Meeting Date 2000, Volume 2, 7-12. Editor(s): Kennedy, John F. Woodhead Publishing Ltd.: Cambridge, UK.
CODEN: 69DKVZ; ISBN: 1-85573-570-9
DOCUMENT TYPE: Conference
LANGUAGE: English

AB When the epithelial cell layer covering two adjacent tissues is removed accidentally or intentionally during surgical procedures, the underlying connective tissue will grow together during the wound- healing process. Similarly, when two connective tissue surfaces not covered by endothelium but sepd. by elastoviscous fluid contg. high mol. wt. **hyaluronan** are wounded by trauma or during surgical procedures, they can grow together during the healing process. Such adhesion between two tissue surfaces may interfere with function and the excessive new connective tissue formed (scar tissue) may exert pressure on adjacent nerves, causing chronic pain. This paper describes the use of new formulations of dry

films contg. only hylan. In animal models, this film prevented adhesion formation between two tissue surfaces denuded from their mesothelial or epithelial cell cover. The most important property of this film after it is hydrated by tissue fluids was that it still adhered to the tissue surface, ensuring its stay in place. Thus, it functions as a barrier material, sepg. the healing tissues. The films do not cause inflammation or foreign body reaction and they do not interfere with the healing of adjacent tissues. These films successfully prevented adhesions between tissue surfaces in liver and cecal abrasion models in rat and uterine horn abrasion models in rabbits. Such films can also be used as delivery vehicles for various drugs, influencing them by combining their phys. barrier effect with regulation effects on the healing process.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:7593 CAPLUS

DOCUMENT NUMBER: 139:127537

TITLE: Anti-cancer activity of **hyaluronan**

AUTHOR(S): Filion, Mario C.; Menard, Sonia; Filion, Benoit; Roy, Julie; Reader, Stephanie; Phillips, Nigel C.

CORPORATE SOURCE: Bioniche Therapeutics Research Centre, Montreal, QC, H4P 2R2, Can.

SOURCE: Hyaluronan, [Proceedings of the International Cellucon Conference], 12th, Wrexham, United Kingdom, 2000 (2002), Meeting Date 2000, Volume 1, 419-427. Editor(s): Kennedy, John F. Woodhead Publishing Ltd.: Cambridge, UK.
CODEN: 69DKVZ; ISBN: 1-85573-570-9

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Although **hyaluronan** (HA) has been shown to modulate cellular proliferation in numerous cell types little is known about its effect on cancer cells. We have evaluated the anti-proliferative activity of HA with a mol. mass of 5.0-7.5.times.105 Da towards a wide range of cancer cell types. We have found that HA at low concns. (< 80 .mu.g/mL) inhibits, in a dose-dependent manner, the cellular proliferation of prostate cancer cells (LNCaP, PC-3, DU-145), bladder cancer cells (HT-1376, RT-4, T24 and UMUC-3), breast cancer cells (MCF-7), melanoma cells (B16-F1) and fibrosarcoma cells (HT-1080). The presence of a no. of escape mechanisms assocd. with cancer progression such as p53/p21 mutations, Rb-mutations, p16 deletion, Fas resistance, absence of caspase-3 and overexpression of P-glycoprotein did not affect the ability of HA to inhibit cancer cell growth. The inhibition of cancer cell proliferation appeared to be independent of the level of expression of the HA receptor CD44. Furthermore, we found that HA potentiated the anti-proliferative activity of anti-cancer agents based on nucleic acids (mycobacterial cell wall complex and Mycobacterium phlei DNA) and of chemotherapeutic drugs (5-**fluorouracil**, cisplatin and tamoxifen). Our data indicates that HA having a mol. mass of 5.0-7.5.times.105 Da has considerable potential for development either as a chemotherapeutic agent or as an adjunct to anti-cancer agents.

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:71908 CAPLUS

DOCUMENT NUMBER: 136:112640

TITLE: **Hyaluronan** as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease

INVENTOR(S): Brown, Tracey; Fox, Richard

PATENT ASSIGNEE(S): Meditech Research Limited, Australia

SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005852	A1	20020124	WO 2001-AU849	20010713
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2368525	A1	20020508	GB 2002-4331	20010713
EP 1301209	A1	20030416	EP 2001-951219	20010713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 760404	B2	20030515	AU 2001-72202	20010713
US 2003180382	A1	20030925	US 2003-88774	20030313

PRIORITY APPLN. INFO.: AU 2000-8795 A 20000714
WO 2001-AU849 W 20010713

AB The present invention relates to the enhancement of bioavailability of chemotherapeutic agents for the treatment of disease. In particular the present invention relates to a method of enhancing the bioavailability of a chemotherapeutic agent comprising the step of administering to a subject in need thereof a therapeutically effective amt. of **hyaluronan**. The present invention also relates to the treatment of a drug resistant disease whereby the drug resistance is overcome or alleviated with the use of **hyaluronan** either alone or in combination with a chemotherapeutic agent. One disease that is frequently affected by both cellular resistance and bioavailability problems is cancer. The present invention also provides a method of treating cancer cells comprising the step of administering to a patient in thereof a therapeutically effective amt. of **hyaluronan**.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1995:341470 CAPLUS
DOCUMENT NUMBER: 123:9822
TITLE: Synthesis and properties of hyaluronic acid conjugated nucleic acid analogs-1: synthesis of deacetylhyaluronan and introduction of nucleic acid bases
AUTHOR(S): Wada, Takehiko; Chirachanchai, Suwabun; Izawa, Naoto; Inaki, Yoshiaki; Takemoto, Kiichi
CORPORATE SOURCE: Faculty of Engineering, Osaka University, Suita, 565, Japan
SOURCE: Journal of Bioactive and Compatible Polymers (1994), 9(4), 429-47
CODEN: JBCPEV; ISSN: 0883-9115
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The conjugation of nucleic acid base with **hyaluronan** was achieved by using the activated ester of pentachlorophenyl trichloroacetate. The conditions of de-N-acetylation of sodium hyaluronic acid were studied. In low concns. of NaOH, the degree of deacetylation was 26%, while in 7.4N NaOH, the degree of deacetylation was 76% and the viscosity was 1.12 dL/g. Thymine and 5-**fluorouracil** bases were quant. conjugated to deacetylhyaluronan in 65% and 51%, resp. The

interaction of thymine **hyaluronan** conjugate with the complementary base of polyadenylate showed a small hypochromicity.

```
=> s L5 and toxicity
        292913 TOXICITY
         10626 TOXICITIES
        296196 TOXICITY
                  (TOXICITY OR TOXICITIES)
L6            2 L5 AND TOXICITY

=> d L6 1-2 ibib abs hitrn
```

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:173470 CAPLUS
DOCUMENT NUMBER: 138:198677
TITLE: Use of **hyaluronan** as a protective agent in chemotherapy for improved therapeutic protocols
INVENTOR(S): Brown, Tracey Jean; Fox, Richard Mark
PATENT ASSIGNEE(S): Meditech Research Limited, Australia
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018062	A1	20030306	WO 2002-AU1160	20020827

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: AU 2001-7302 A 20010827
AU 2001-9504 A 20011213

AB The invention relates to the field of chemotherapy of diseases, e.g. cell proliferation disorders including cancer. In particular, the invention discloses the use of **hyaluronan** (HA) as a protective agent in the treatment of subjects. HA is administered in conjunction with a chemotherapeutic agent to facilitate the prolonged administration of a dose of the chemotherapeutic agent to be administered to a subject. Owing to the protective effects of the HA, the dose of chemotherapeutic agent may be substantially higher than a generally accepted ED, which would otherwise be expected to cause unacceptable side effects in the subject.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:71908 CAPLUS
DOCUMENT NUMBER: 136:112640
TITLE: **Hyaluronan** as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
INVENTOR(S): Brown, Tracey; Fox, Richard
PATENT ASSIGNEE(S): Meditech Research Limited, Australia
SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005852	A1	20020124	WO 2001-AU849	20010713
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2368525	A1	20020508	GB 2002-4331	20010713
EP 1301209	A1	20030416	EP 2001-951219	20010713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AU 760404	B2	20030515	AU 2001-72202	20010713
US 2003180382	A1	20030925	US 2003-88774	20030313

PRIORITY APPLN. INFO.: AU 2000-8795 A 20000714
WO 2001-AU849 W 20010713

AB The present invention relates to the enhancement of bioavailability of chemotherapeutic agents for the treatment of disease. In particular the present invention relates to a method of enhancing the bioavailability of a chemotherapeutic agent comprising the step of administering to a subject in need thereof a therapeutically effective amt. of **hyaluronan**. The present invention also relates to the treatment of a drug resistant disease whereby the drug resistance is overcome or alleviated with the use of **hyaluronan** either alone or in combination with a chemotherapeutic agent. One disease that is frequently affected by both cellular resistance and bioavailability problems is cancer. The present invention also provides a method of treating cancer cells comprising the step of administering to a patient in thereof a therapeutically effective amt. of **hyaluronan**.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> stnguide
STNGUIDE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	66.30	66.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.02	-13.02

FILE 'STNGUIDE' ENTERED AT 10:55:14 ON 10 OCT 2003

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Oct 3, 2003 (20031003/UP).